Lithium Does Not Affect Apixaban Anticoagulation
A patient on long-term lithium therapy can be adequately anticoagulated with apixaban (Eliquis) - lithium does not interact with apixaban and does not affect its anticoagulant efficacy or safety profile.
Why This Works
Apixaban is a direct factor Xa inhibitor with well-characterized pharmacokinetics that are not affected by lithium:
Metabolism and Elimination: Apixaban undergoes multiple elimination pathways including CYP3A4 metabolism (minimal), biliary excretion, direct intestinal excretion, and renal excretion (27% of total clearance) 1, 2. Lithium does not interact with any of these pathways.
No Drug-Drug Interaction: The primary drug interactions with apixaban involve combined P-glycoprotein (P-gp) and strong CYP3A4 inhibitors or inducers 1, 3. Lithium is neither a P-gp modulator nor a CYP3A4 inhibitor/inducer, so no pharmacokinetic interaction exists.
Proper Apixaban Dosing
For atrial fibrillation (most common indication), the standard dose is 5 mg twice daily 4, 1. Reduce to 2.5 mg twice daily ONLY if the patient has at least 2 of the following 3 criteria 4, 5, 1:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (133 μmol/L)
For VTE treatment: 10 mg twice daily for 7 days, then 5 mg twice daily 6, 7, 1.
Critical Monitoring Considerations
While lithium doesn't affect apixaban, you must monitor for:
Renal function: Both lithium and apixaban require dose adjustments in renal impairment 8, 1. Check creatinine clearance regularly, as lithium can cause chronic kidney disease which would necessitate apixaban dose reduction.
Bleeding risk factors: Lithium-induced thrombocytopenia or platelet dysfunction (rare but reported) could theoretically increase bleeding risk when combined with anticoagulation. Monitor CBC periodically.
Avoid inappropriate dose reduction: Studies show 41% of patients on apixaban 2.5 mg for AF receive potentially inappropriate doses 9, 10. Don't reduce apixaban dose based on perceived bleeding risk from lithium alone - follow the strict dose-reduction criteria above.
Common Pitfall to Avoid
Do not empirically reduce apixaban dose simply because the patient is on lithium or has a history of lithium-related side effects. The evidence shows that inappropriate underdosing of apixaban increases thromboembolic risk without reducing bleeding 9. Use only the FDA-approved dose-reduction criteria 1.
If the patient develops significant renal impairment from lithium (CrCl 15-29 mL/min), reduce apixaban to 2.5 mg twice daily for AF 8. If CrCl <15 mL/min or on dialysis, apixaban 5 mg twice daily can still be used but consider 2.5 mg twice daily if age ≥80 years or weight ≤60 kg 8, 1.